Home > Publications database > Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. |
Journal Article | DKFZ-2017-03324 |
; ; ; ; ; ; ; ; ; ; ;
2015
Academic Press
San Diego, Calif.
This record in other databases:
Please use a persistent id in citations: doi:10.1016/j.ygeno.2015.10.002
Abstract: DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
Keyword(s): Antimetabolites, Antineoplastic ; Cell Adhesion Molecules ; GPI-Linked Proteins ; Hyal2 protein, human ; Hyaluronoglucosaminidase ; Fluorouracil
![]() |
The record appears in these collections: |